Clinical studies on the use of roxatidine acetate for the treatment of peptic ulcer in Japan
1. 请及时下载文件确认是否正确, 系统将在 2026-10-19 16:11:37 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
M Inoue
Drugs, 1988
Springer
Roxatidine acetate is a novel H2-receptor antagonist with a chemical structure different to the earlier drugs of this type. It is a potent inhibitor of histamine-mediated gastric acid secretion and in animal models is 4 to 6 times as potent as cimetidine. In a multicentre double-blind clinical trial of over 700 patients with gastric or duodenal ulcers roxatidine acetate 75mg twice daily and cimetidine 200mg four times daily produced endoscopically confirmed and subjective and objective healing rates in excess of 90% for both types of …
